[The antihypertensive efficacy and tolerance of bopindolol (LT 31-200) in hypertensive patients].
A open study with increasing doses of bopindolol, a nonselective beta-blocker of long half-life has been carried out in patients with mild and moderate hypertension in order to assess the efficacy and security of the treatment in short and long term. Twenty patients (22 women and 8 men) were included with the ranging ages from 36 to 62 years old (x +/- SD 51.6 +/- 7.6) whose blood pressures were higher than 160 mm Hg for the systolic value and between 90 and 125 mm Hg for the diastolic (x +/- SD 165 +/- 7.2 and 102.6 +/- 6.7 respectively). Nineteen from the twenty patients (95%) responded satisfactorily after 20 weeks of oral bopindolol treatment once a day showing significative statistical differences on forth week of the treatment versus blood pressure rates of placebo's period. Similar results were obtained with regard to the cardiac frequency. HDL cholesterol rates increased significantly as well as the ratio HDL cholesterol/total cholesterol.
Honorato
J
J
Servicio de Farmacología Clínica, Clínica Universitaria de Navarra.
Galende
I
I
Catalán
M
M
Azanza
J R
JR
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D010869:Pindolol; C036007:bopindolol